Overview
United BioSource Corporation (UBC) announced on April 21, 2005 that it acquired Dynarand, Inc, a San Francisco, California-based specialist in clinical research support technology.
UBC delivers evidence-based services to enhance the medical and commercial potential of pharmaceuticals, biologics, medical devices and diagnostics.
Dynarand is a privately held company that develops and manages clinical study technology solutions.
Significance
The acquisition is part of the UBC strategy of building integrated capabilities to meet growing demand by the pharmaceutical and biotech sectors for evidence-based services to demonstrate the effectiveness, manage safety, and document economic value associated with their products.
“UBC is focused on helping pharmaceutical companies obtain scientific evidence to support the use of their products. Dynarand’s technology platform and their commitment to client service are critical new assets for us,” said UBC Founder and CEO Ethan Leder.
“We will continue to build and enhance Dynarand’s technology and intend to leverage these products as we design and implement evidence-based product support services for all our customers. With Dynarand, UBC now offers the industry’s best technology for enhancing efficiency, reliability, and cost effectiveness of clinical trials,” Leder added.
Crosstree’s Role
Crosstree Capital Partners was the exclusive financial advisor for Dynarand, LLC.
Latest Deals
Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe
.png)
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally
.png)
Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering
Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities
Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities
VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities
Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings
Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities
Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities
ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally
anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally
OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials
